Jianshan Mo

718 total citations · 1 hit paper
15 papers, 477 citations indexed

About

Jianshan Mo is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Jianshan Mo has authored 15 papers receiving a total of 477 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Molecular Biology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Jianshan Mo's work include Cytokine Signaling Pathways and Interactions (5 papers), Cancer Mechanisms and Therapy (4 papers) and Synthesis and biological activity (2 papers). Jianshan Mo is often cited by papers focused on Cytokine Signaling Pathways and Interactions (5 papers), Cancer Mechanisms and Therapy (4 papers) and Synthesis and biological activity (2 papers). Jianshan Mo collaborates with scholars based in China, Macao and United States. Jianshan Mo's co-authors include Xiaolei Zhang, Shumin Ouyang, Yuanxiang Wang, Kai Zhu, Ziyou Lin, Huaxuan Li, Wen Ding, Peibin Yue, James Turkson and Linlin Lou and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and Advanced Science.

In The Last Decade

Jianshan Mo

14 papers receiving 471 citations

Hit Papers

Inhibition of STAT3-ferroptosis negative regulatory axis ... 2022 2026 2023 2024 2022 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer
    2022 323 citations Shumin Ouyang, Huaxuan Li et al. Redox Biology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jianshan Mo China 7 271 228 179 150 62 15 477
Shumin Ouyang China 9 378 1.4× 253 1.1× 229 1.3× 178 1.2× 67 1.1× 19 640
Linlin Lou China 7 297 1.1× 212 0.9× 170 0.9× 104 0.7× 28 0.5× 10 483
Lin Zhong China 9 304 1.1× 221 1.0× 220 1.2× 111 0.7× 42 0.7× 21 523
Nicoletta Chicchinelli Italy 9 184 0.7× 156 0.7× 192 1.1× 184 1.2× 58 0.9× 12 453
Ryan L. Shuck United States 13 363 1.3× 158 0.7× 203 1.1× 180 1.2× 48 0.8× 21 556
Daniela Frezzetti Italy 13 358 1.3× 110 0.5× 266 1.5× 175 1.2× 47 0.8× 18 613
Jianzheng Zhu China 3 222 0.8× 197 0.9× 157 0.9× 74 0.5× 24 0.4× 6 376
Prabhjot S. Mundi United States 9 290 1.1× 111 0.5× 92 0.5× 175 1.2× 87 1.4× 27 490
Sara G. Manore United States 9 313 1.2× 82 0.4× 126 0.7× 256 1.7× 70 1.1× 13 579
Conghua Lu China 13 295 1.1× 181 0.8× 96 0.5× 190 1.3× 47 0.8× 39 528

Countries citing papers authored by Jianshan Mo

Since Specialization
Citations

This map shows the geographic impact of Jianshan Mo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianshan Mo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianshan Mo more than expected).

Fields of papers citing papers by Jianshan Mo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jianshan Mo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianshan Mo. The network helps show where Jianshan Mo may publish in the future.

Co-authorship network of co-authors of Jianshan Mo

This figure shows the co-authorship network connecting the top 25 collaborators of Jianshan Mo. A scholar is included among the top collaborators of Jianshan Mo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jianshan Mo. Jianshan Mo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Ouyang, Shumin, Ziyou Lin, Mei Lü, et al.. (2025). The IGF2BP3–FASN axis drives lipid metabolic reprogramming to promote brain colonization in non-small cell lung cancer. Cell Death and Disease. 16(1). 684–684.
2.
Mo, Jianshan, Qiyi Zhang, Liu Guang, et al.. (2025). Metabolic reprogramming of tumor-associated macrophages via adenosine-A2AR signaling drives cross-resistance in non-small cell lung cancer. Drug Resistance Updates. 82. 101272–101272. 4 indexed citations
3.
Wang, Pengyan, Wen Ding, Jianshan Mo, et al.. (2025). A novel adenosine 2A receptor antagonist HZ-086 enhances the efficiency of immunotherapy and alleviates the acquired resistance to PD-L1 by restoration of T cell functions. European Journal of Pharmacology. 997. 177535–177535. 1 indexed citations
4.
Ding, Wen, Jianzheng Zhu, Jianshan Mo, et al.. (2025). Neuropeptide Precursor VGF Promotes Neuroendocrine Differentiation and Cancer-Associated Fibroblast Activation in Small Cell Lung Cancer. Cancer Research. 85(22). 4469–4484. 2 indexed citations
5.
Lou, Linlin, Shumin Ouyang, Jianshan Mo, et al.. (2025). Periostin-mediated NOTCH1 activation between tumor cells and HSCs crosstalk promotes liver metastasis of small cell lung cancer. Journal of Experimental & Clinical Cancer Research. 44(1). 6–6. 1 indexed citations
6.
Zhang, Qiyi, Wen Ding, Jianshan Mo, et al.. (2024). Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma. Acta Pharmacologica Sinica. 45(8). 1701–1714. 8 indexed citations
7.
Ding, Wen, et al.. (2024). Novel artemisinin derivative P31 inhibits VEGF-induced corneal neovascularization through AKT and ERK1/2 pathways. Heliyon. 10(8). e29984–e29984. 1 indexed citations
8.
Ouyang, Shumin, Shuo Shi, Ge Yang, et al.. (2024). Neuropeptide Precursor VGF Promotes Liver Metastatic Colonization of Gαq Mutant Uveal Melanoma by Facilitating Tumor Microenvironment via Paracrine Loops. Advanced Science. 11(46). e2407967–e2407967. 3 indexed citations
9.
He, Xinyu, Wen-Yu Lyu, Mu‐Yang Huang, et al.. (2023). Identification of Bulbocodin D and C as novel STAT3 inhibitors and their anticancer activities in lung cancer cells. Chinese Journal of Natural Medicines. 21(11). 842–851. 4 indexed citations
10.
Kang, Zhenghui, Jianshan Mo, Ziyou Lin, et al.. (2023). Discovery and Optimization of Novel Biphenyl Derivatives Bearing Cyclopropyl Linkage as Potent Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors. Journal of Medicinal Chemistry. 66(10). 6811–6835. 17 indexed citations
11.
Deng, Linhong, Jianshan Mo, Yi Zhang, et al.. (2022). Boronic Acid: A Novel Pharmacophore Targeting Src Homology 2 (SH2) Domain of STAT3. Journal of Medicinal Chemistry. 65(19). 13094–13111. 9 indexed citations
12.
Ouyang, Shumin, Huaxuan Li, Linlin Lou, et al.. (2022). Inhibition of STAT3-ferroptosis negative regulatory axis suppresses tumor growth and alleviates chemoresistance in gastric cancer. Redox Biology. 52. 102317–102317. 323 indexed citations breakdown →
13.
Zhong, Yan, Linhong Deng, Shuo Shi, et al.. (2021). The novel STAT3 inhibitor WZ-2-033 causes regression of human triple-negative breast cancer and gastric cancer xenografts. Acta Pharmacologica Sinica. 43(4). 1013–1023. 27 indexed citations
14.
Zhong, Yan, Bingbing Li, Shumin Ouyang, et al.. (2021). Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3). European Journal of Medicinal Chemistry. 221. 113525–113525. 9 indexed citations
15.
Dong, Hui, Jianshan Mo, Yi Zhang, et al.. (2020). A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance. Theranostics. 11(2). 824–840. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shumin Ouyang Breakdown of academic impact, for papers by Linlin Lou Breakdown of academic impact, for papers by Lin Zhong Breakdown of academic impact, for papers by Nicoletta Chicchinelli Breakdown of academic impact, for papers by Ryan L. Shuck Breakdown of academic impact, for papers by Daniela Frezzetti Breakdown of academic impact, for papers by Jianzheng Zhu Breakdown of academic impact, for papers by Prabhjot S. Mundi Breakdown of academic impact, for papers by Sara G. Manore Breakdown of academic impact, for papers by Conghua Lu
Rankless by CCL
2026